hrcak mascot   Srce   HID

Pregledni rad
https://doi.org/10.5562/cca1819

Cyclic Lipodepsipeptides in Novel Antimicrobial Drug Discovery

Nina Bionda ; Torrey Pines Institute for Molecular Studies, 11350 SW Village Parkway, Port St. Lucie, FL 34987, USA
Predrag Cudic ; Torrey Pines Institute for Molecular Studies, 11350 SW Village Parkway, Port St. Lucie, FL 34987, USA

Puni tekst: engleski, pdf (7 MB) str. 315-329 preuzimanja: 1.664* citiraj
APA 6th Edition
Bionda, N. i Cudic, P. (2011). Cyclic Lipodepsipeptides in Novel Antimicrobial Drug Discovery. Croatica Chemica Acta, 84 (2), 315-329. https://doi.org/10.5562/cca1819
MLA 8th Edition
Bionda, Nina i Predrag Cudic. "Cyclic Lipodepsipeptides in Novel Antimicrobial Drug Discovery." Croatica Chemica Acta, vol. 84, br. 2, 2011, str. 315-329. https://doi.org/10.5562/cca1819. Citirano 04.03.2021.
Chicago 17th Edition
Bionda, Nina i Predrag Cudic. "Cyclic Lipodepsipeptides in Novel Antimicrobial Drug Discovery." Croatica Chemica Acta 84, br. 2 (2011): 315-329. https://doi.org/10.5562/cca1819
Harvard
Bionda, N., i Cudic, P. (2011). 'Cyclic Lipodepsipeptides in Novel Antimicrobial Drug Discovery', Croatica Chemica Acta, 84(2), str. 315-329. https://doi.org/10.5562/cca1819
Vancouver
Bionda N, Cudic P. Cyclic Lipodepsipeptides in Novel Antimicrobial Drug Discovery. Croatica Chemica Acta [Internet]. 2011 [pristupljeno 04.03.2021.];84(2):315-329. https://doi.org/10.5562/cca1819
IEEE
N. Bionda i P. Cudic, "Cyclic Lipodepsipeptides in Novel Antimicrobial Drug Discovery", Croatica Chemica Acta, vol.84, br. 2, str. 315-329, 2011. [Online]. https://doi.org/10.5562/cca1819

Sažetak
Naturally occurring cyclic depsipeptides, microbial secondary metabolites that contain one or
more ester bonds in addition to the amide bonds, have emerged as an important source of pharmacologically
active compounds or promising lead structures for the development of novel synthetically derived
drugs. In particular, their lipidated derivatives have shown the greatest therapeutic potential as antimicrobial
agents. Some of those compounds are either already marketed (daptomycin 37) or in advanced
stages of clinical development (ramoplanin 32) for the treatment of complicated infections caused by multidrug-
resistant bacterial strains. As bacteria progressively become resistant to frontline antimicrobial
agents, our capacity to effectively treat bacterial infections becomes severely hindered. Therefore, identifying
novel antibacterial targets and new antibacterial chemotherapeutics capable of treating infections
from drug-resistant microorganisms is of vital importance.(doi: 10.5562/cca1819)

Ključne riječi
antibiotic; cyclic; lipodepsipeptide

Hrčak ID: 71994

URI
https://hrcak.srce.hr/71994

Posjeta: 1.982 *